The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling.
about
Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphomaInterplay of Murine Gammaherpesvirus 68 with NF-kappaB Signaling of the HostFLIP and the death effector domain familyViral FLICE inhibitory protein of rhesus monkey rhadinovirus inhibits apoptosis by enhancing autophagosome formationInhibition of NF-kappaB activation in vivo impairs establishment of gammaherpesvirus latency.Molecular biology of KSHV in relation to AIDS-associated oncogenesis.Allosteric regulation of the ubiquitin:NIK and ubiquitin:TRAF3 E3 ligases by the lymphotoxin-beta receptor.Molecular biology of human herpesvirus 8: novel functions and virus-host interactions implicated in viral pathogenesis and replication.Efficacy of bortezomib in a direct xenograft model of primary effusion lymphomaKaposi Sarcoma Pathogenesis: A Triad of Viral Infection, Oncogenesis and Chronic Inflammation.Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesisA20/TNFAIP3 inhibits NF-κB activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein.TRAF molecules in cell signaling and in human diseasesUnderstanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.Gene regulation and functional alterations induced by Kaposi's sarcoma-associated herpesvirus-encoded ORFK13/vFLIP in endothelial cells.Cross-regulation between herpesviruses and the TNF superfamily membersNF-κB as a target for oncogenic viruses.A role for MALT1 activity in Kaposi's sarcoma-associated herpes virus latency and growth of primary effusion lymphoma.Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention.Structural studies of NF-κB signaling.Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patientsThe Ubiquitin System and Kaposi's Sarcoma-Associated Herpesvirus.Review of latent and lytic phase biomarkers in Kaposi's sarcoma.An overview of new biomolecular pathways in pathogen-related cancers.Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.Kaposi's sarcoma-associated herpesvirus (KSHV) oncoprotein K13 bypasses TRAFs and directly interacts with the IkappaB kinase complex to selectively activate NF-kappaB without JNK activation.microRNA dependent and independent deregulation of long non-coding RNAs by an oncogenic herpesvirus.NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo.Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis.FLIP-mediated autophagy regulation in cell death control.Dynamic change of TNIK in response to tumor necrosis factor alpha in a TRAF2-dependent manner.A parapoxviral virion protein targets the retinoblastoma protein to inhibit NF-κB signaling.Kaposi's Sarcoma-Associated Herpesvirus: Epidemiology and Molecular Biology.Peroxisomes support human herpesvirus 8 latency by stabilizing the viral oncogenic protein vFLIP via the MAVS-TRAF complex.Genetic Alterations of TRAF Proteins in Human Cancers
P2860
Q21135231-FE501D5E-8316-4322-A241-3798884ABC1FQ28080198-41434FD8-BB4C-46BC-9431-AA01C378B50AQ28297969-BEF86F4A-9025-440A-A580-3E2478B65637Q28480552-96152F09-064E-493A-AA15-461E2D011110Q33270518-D6243069-10F5-4C7A-8EB0-12510DE98FB3Q33560572-03138F3C-9AA0-44A4-8D96-B599498BE353Q33883378-46183A12-5050-46E8-AA5E-60083F23F1A2Q34013830-FA68B099-5DD8-4C1A-B4FE-8808BF4EEF10Q34059058-E8707357-5BFB-427F-B019-FB839B7DD3BEQ34644229-741C0A50-4F0E-4D4E-A188-1321D6687FDAQ35124404-CC6C8E42-1CB4-4D00-9419-FB721626FE78Q36673788-8A7A076F-CD6F-403E-9523-B36C83E6153DQ36972287-C604091F-D04B-4CBB-87B5-435964D1D64AQ37088015-60922A20-8AA0-45DE-AC00-C17649015AAAQ37099734-61D6ADCE-A7CC-4A0D-BD17-0474CDEF77A3Q37307520-2D1FA854-3BB0-44DE-A8C3-82A75E023D18Q37374081-D87DADFA-3505-49DD-9A2A-F7708201D49EQ37683385-226043F7-23CA-43AF-96B6-9E65DED1F9FBQ37810431-A7FD49E9-E09A-4815-8DB4-0C975E3663A5Q37816940-A953BA7E-D9BA-480E-8D06-A08BC00C8928Q37865141-B49ECE70-2D30-47C3-82A6-410E5BD0A2ECQ37989143-AA587EB5-B4DE-46B0-9B3D-125A3247B9C8Q38144129-8C8F10B9-5CFE-45A0-98F5-024AF2BB7157Q38515827-52019C22-E117-4AFD-8B04-C0F4451B41C6Q39176686-169A2752-51CF-4D3E-BD4C-86C0ABA4C570Q40114329-530D342B-52E4-4931-AA4D-E2982F7B4A6AQ40120040-04EE518F-4F5B-4E38-8EE4-95767378CC53Q40335673-03C5225D-860D-4561-965F-89405F13C05AQ41861701-7A59C2C5-2B03-415C-BAAB-F5110ED1FD8FQ42832950-0D71B6B9-D88E-49CB-92DA-955CBF5A2BB4Q46132376-85468FC1-62DF-4EA6-A001-2ABCE208D6B4Q47289904-E1E957A0-440C-44EB-87C9-8F58F36CE2FAQ47606321-CAA46C6F-F4B7-4040-A570-498E9FA11043Q54983421-7211A0E2-E411-4C84-8A0B-26EF61658550Q57191736-D122DC86-9D21-46C5-ADF7-C9FC8A8F1E7B
P2860
The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signalling.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The KSHV oncoprotein vFLIP con ...... TRAF2 and TRAF3 for signalling
@nl
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@ast
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@en
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@en-gb
type
label
The KSHV oncoprotein vFLIP con ...... TRAF2 and TRAF3 for signalling
@nl
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@ast
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@en
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@en-gb
prefLabel
The KSHV oncoprotein vFLIP con ...... TRAF2 and TRAF3 for signalling
@nl
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@ast
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@en
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@en-gb
P2093
P2860
P3181
P356
P1433
P1476
The KSHV oncoprotein vFLIP con ...... RAF2 and TRAF3 for signalling.
@en
P2093
Ethel Cesarman
Ilaria Guasparri
P2860
P304
P3181
P356
10.1038/SJ.EMBOR.7400580
P407
P577
2006-01-01T00:00:00Z